Toxicity Profiles
Toxicity Summary for SILVER
NOTE:
Although the toxicity values presented in these toxicity profiles
were correct at the time they were produced, these values are subject to change.
Users should always refer to the
Toxicity Value Database
for the current toxicity values.
DECEMBER 1992
Prepared by: Rosmarie A. Faust, Ph.D., Chemical Hazard Evaluation and Communication Group,
Biomedical and Environmental Information Analysis Section, Health and Safety Research Division,
*, Oak Ridge, Tennessee.
Prepared for: Oak Ridge Reservation Environmental Restoration Program.
*Managed by Martin Marietta Energy Systems, Inc., for the U.S. Department of Energy under
Contract No. DE-AC05-84OR21400.
Silver is a relatively rare metal that occurs naturally in the earth's crust and is released to the
environment from various industrial sources. Human exposure to silver and silver compounds can
occur orally, dermally, or by inhalation. Silver is found in most tissues, but has no known physiologic function.
In humans, accidental or intentional ingestion of large doses of silver nitrate has produced
corrosive damage of the gastrointestinal tract, abdominal pain, diarrhea, vomiting, shock, convulsions, and death (U.S. EPA, 1985). Respiratory irritation was noted following acute inhalation
exposure to silver or silver compounds. Silver nitrate solutions are highly irritating to the skin,
mucous membranes, and eyes (Stokinger, 1981).
Ingestion, inhalation, or dermal absorption of silver may cause argyria, the most common indicator
of long-term exposure to silver or silver compounds in humans. Argyria is a gray or blue-gray,
permanent discoloration of the skin and mucous membranes that is not a toxic effect per se, but is
considered cosmetically disfiguring. Chronic inhalation exposure of workers to silver oxide and
silver nitrate dusts resulted in upper and lower respiratory irritation, deposition of granular silver-containing deposits in the eyes, impaired night vision, and abdominal pain (Rosenman et al., 1979).
Mild allergic responses have been attributed to dermal contact with silver (ATSDR, 1990).
In long-term oral studies with experimental animals, silver compounds have produced slight
thickening of the basement membranes of the renal glomeruli, growth depression, shortened
lifespan, and granular silver-containing deposits in skin, eyes, and internal organs (Matuk et al.,
1981; Olcott, 1948, 1950). Hypoactivity was seen in rats subchronically exposed to silver nitrate
in drinking water (Rungby and Danscher, 1984).
A Reference Dose (RfD) of 0.005 mg/kg/day for subchronic and chronic exposure was calculated
from a lowest-observed-adverse-effect level (LOAEL) of 0.014 mg/kg/day for argyria observed in
patients receiving i.v. injections of silver arsphenamine (U.S. EPA, 1992a,b). Data are presently
insufficient to derive a Reference Concentration (RfC) for silver (U.S. EPA, 1992a).
Data adequate for evaluating the carcinogenicity of silver to humans or animals by ingestion,
inhalation, or other routes of exposure were not found. Based on U.S. EPA guidelines, silver is
placed in weight-of-evidence group D, not classifiable as to human carcinogenicity (U.S. EPA,
1992a).
Retrieve Toxicity Profiles
Formal Version
Last Updated 2/13/98
|